[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-434140-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-434140-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","fertility-preservation-in-women-with-sarcoma-a-real-world-experience","Fertility preservation in women with sarcoma: A real-world experience","","Sarcomas frequently affect adolescent girls and young women, making future fertility a critical concern. Limited time before chemotherapy, driven by rapid progression and extensive diagnostic work-up, often restricts access to fertility preservation. This observational cohort study assesses feasibility, timing, and clinical relevance of fertility preservation in young women treated for high-grade sarcomas or desmoid tumors at Cochin Hospital, AP-HP, emphasizing long-term ovarian function and reproductive outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/fertility-preservation-in-women-with-sarcoma-a-real-world-experience/434140/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/fertility-preservation-in-women-with-sarcoma-a-real-world-experience/434140.png","ImageObject",300,407,{"name":42,"@type":43},"Rhys","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-29",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is fertility preservation challenging in young women with sarcoma?","Question",{"text":63,"@type":64},"Treatment urgency from rapid tumor progression and the need for extensive staging and diagnostic evaluation can reduce the time available to complete fertility preservation before chemotherapy.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What proportion of patients resumed ovarian function after treatment?",{"text":68,"@type":64},"Among patients assessed for post-treatment ovarian function, 77% resumed menstruation, and recovery was commonly observed over follow-up.",{"name":70,"@type":61,"acceptedAnswer":71},"What fertility preservation methods were used and were cryopreserved tissues used later?",{"text":72,"@type":64},"Thirteen patients underwent oocyte or ovarian tissue cryopreservation before or early during treatment, but no patient used cryopreserved oocytes or ovarian tissue at last follow-up; one patient underwent fertility preservation after therapy.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},434140,1790873869,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":102,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},687207024643,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","DOI: 10.1002/ijc.70260  \nSHORT REPORT  \nCancer Therapy a nd Prevention  \nFertility preservation in women with sarcoma: A real-world experience  \nGuillaume Beinse 1,2 | Pascaline Boudou-Rouquette 1  | Sixtine de Percin 1 | Anne Fortin 3 | Johanna Noel 1 | Sarah Kreps 4 | Jérémy Sroussi 5 | Virginie Barraud-Lange 6 | Jérôme Alexandre 1,2  | François Goldwasser 1,2 | Camille Tlemsani 1,2  | Catherine Poirot 7   \n1Department of Oncology, APHP, Cochin Hospital, University Paris Cité, Paris, France 2University Paris Cité, Paris, France 3Department of Obstetrics Gynecology, Clinique Gaston Metivet, Saint Maur des Fossés, France  \n4Department of Radiation Oncology, APHP, Georges Pompidou European Hospital, University Paris Cité, Paris, France 5Department of Obstetrics Gynecology, APHP, Lariboisière Hospital, University Paris Cité, Paris, France  \n6Department of Reproductive Biology, APHP Center, Cochin Hospital, University Paris Cité, Paris, France  \n7Department of Hematology, Adolescents and Young Adults Unit, Fertility Preservation, APHP, Saint Louis Hospital, Paris, France  \nCorrespondence  \nCamille Tlemsani, Department of Oncology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France.  \nEmail: [camille.tlemsani@aphp.fr](camille.tlemsani@aphp.fr)  \nAbstract  \nSarcomas frequently affect adolescent girls and young women, for whom future fertility is a critical concern. The urgency of initiating treatment—due to rapid tumor progression and the need for extensive diagnostic evaluation—often limits the window for fertility preservation prior to chemotherapy. However, emerging evidence indicates that gonadotoxicity is variable, and ovarian function may be preserved in a substantial number of cases. This observational cohort study evaluates the feasibility, timing, and clinical relevance of fertility preservation in young women treated for high-grade sarcomas or desmoid tumors at Cochin Hospital, AP-HP (Paris, France), with a focus on long-term ovarian function and reproductive outcomes. Among 59 patients (median age at first oncology consultation, 24.3 years), 13 underwent oocyte or ovarian tissue cryopreservation before or early during treatment. Therapy regimens included alkylating and non-alkylating chemotherapies, radiotherapy, or combinations thereof. At last follow-up, 49 women were alive, and 27 had experienced relapse or progression. Among 26 patients assessed for post-treatment ovarian function (median follow-up 62 months), 77% resumed menstruation, 27% conceived naturally, 78% of those actively attempting pregnancy were naturally successful, and 19% gave birth. No patient used cryopreserved oocytes or ovarian tissue. One patient underwent fertility preservation after therapy. These results suggest that systematic fertility preservation may not be mandatory for all patients and that spontaneous ovarian function recovery is common. The observed pregnancy outcomes underscore the importance of personalized, patient-centered fertility counseling based on tumor characteristics and treatment modalities.  \nAbbreviations: AMH, Anti-Müllerian hormone; DT, desmoid tumor; ES, Ewing sarcoma; FP, fertility preservation; IQR, interquartile range; OS, osteosarcoma; STS, soft tissue sarcoma.  \nGuillaume Beinse and Pascaline Boudou-Rouquette contributed equally to this study.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2025 The Author(s) . International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.  \nKEYWOR DS  \nfertility preservation, gonadotoxic treatment, reproductive counseling, sarcoma, young adult oncology  \nWhat's New?  \nSarcomas frequently affect adolescent girls and young women, but limited data exist on ovarian function following sarcoma treatment","cbCaii10R71PNXPG","https://ap.wps.com/l/cbCaii10R71PNXPG","pdf",568177,"English","# Abstract\n# What's New?\n# Introduction\n# Materials and Methods","[{\"question\":\"Why is fertility preservation challenging in young women with sarcoma?\",\"answer\":\"Treatment urgency from rapid tumor progression and the need for extensive staging and diagnostic evaluation can reduce the time available to complete fertility preservation before chemotherapy.\"},{\"question\":\"What proportion of patients resumed ovarian function after treatment?\",\"answer\":\"Among patients assessed for post-treatment ovarian function, 77% resumed menstruation, and recovery was commonly observed over follow-up.\"},{\"question\":\"What fertility preservation methods were used and were cryopreserved tissues used later?\",\"answer\":\"Thirteen patients underwent oocyte or ovarian tissue cryopreservation before or early during treatment, but no patient used cryopreserved oocytes or ovarian tissue at last follow-up; one patient underwent fertility preservation after therapy.\"}]","Fertility preservation in women with sarcoma: A real-world experience | PDF",1790667245,15]